Wanbury Reports Q2 Revenue of ₹183 Crore Versus ₹160 Crore YoY

Market snapshot: Wanbury Limited announced its Q2 revenue at ₹183 crore, registering an expansion compared to ₹160 crore in the corresponding quarter of the previous financial year. The top-line performance reflects sustained demand across its active pharmaceutical ingredient and formulations portfolios.

Data Snapshot

• Q2 Revenue stood at ₹183 crore, up from ₹160 crore in the year-ago period.
• Prior year comparative Q2 revenue was recorded at ₹160.06 crore.

What's Changed

• Q2 top-line increased to ₹183 crore from ₹160 crore YoY, achieving a revenue growth of ≈14.38% YoY (derived: ₹183 cr vs ₹160 cr).

Key Takeaways

• Top-line expanded to ₹183 crore in Q2, demonstrating steady operational volume growth.
• Recent international customer wins in Saudi Arabia and Mexico provide incremental multi-year revenue visibility.
• USFDA approval clearances with nine No DMF Deficiency letters strengthen the company's export positioning.

SAHI Perspective

Wanbury's revenue trajectory demonstrates steady top-line expansion, backed by increasing momentum in active pharmaceutical ingredients. The growth trajectory is reinforced by non-infringing process validation and regulatory approvals in export markets.

Market Implications

The top-line growth confirms volume recovery in core active pharmaceutical ingredient product categories. Steady execution in commercializing Metformin formulations across Latin America and the Middle East supports medium-term cash flow stability.

Trading Signals

Market Bias: Bullish

Revenue expansion to ₹183 crore from ₹160 crore YoY highlights improving core operating momentum. Directional positive bias is supported by verified international order wins and USFDA regulatory clearances.

Overweight: Pharmaceutical APIs, Formulations Exports

Trigger Factors:

• Sustained revenue growth above ₹180 crore in subsequent quarters
• Margin trajectory updates in full detailed financial disclosures
• Execution of commercialization timelines in Saudi Arabia and Mexico

Time Horizon: Near-term (0-3 months)

Industry Context

India's active pharmaceutical ingredients sector continues to benefit from supply chain diversification globally and increased regulatory compliances for key active ingredients.

Key Risks to Watch

• Volatility in raw material costs for active pharmaceutical ingredients
• Regulatory updates or inspection outcomes at key manufacturing facilities
• Foreign exchange volatility in international export markets

Recent Developments

In October 2026, Wanbury received nine No DMF Deficiency letters from the USFDA for its Metformin HCl Drug Master File. Additionally, the company commercialised a Metformin DC business in Saudi Arabia with an estimated annual revenue potential of ₹10 crore and secured supplier allocation for a two-year Mexico tender valued at ₹15 crore per annum.

Closing Insight

Wanbury's quarterly revenue expansion to ₹183 crore reflects fundamental execution across API markets, bolstered by recent international regulatory clearances.

High Performance Trading with SAHI.